Fulltext

Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs

Østensen, M. ; Lockshin, M. ; Doria, A. ; Valesini, G. ; Meroni, P. ; Gordon, C. ; Brucato, A. ; Tincani, A.

In: Rheumatology, 2008, vol. 47, p. iii28-iii31

Ajouter à la liste personnelle
    Titre
    • Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs
    Auteur
    • Østensen, M.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Lockshin, M.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Doria, A.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Valesini, G.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Meroni, P.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Gordon, C.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Brucato, A.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    • Tincani, A.. Department of Rheumatology and Clinical Immunology and Allergology, University Hospital of Bern, Bern, Switzerland Joan and Sanford Weill College of Medicine of Cornell University, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, USA Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova Cattedra di Reumatologia, University ‘La Sapienza', Rome Department of Internal Medicine, University of Milan, Allergy, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK Department of Internal Medicine, Ospedali Riuniti, Bergamo Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:289434
    Summary
    A consensus paper concerning the interaction of anti-rheumatic drugs and reproduction was published in 2006, representing data collected during the year 2004 and 2005. Because of an increasing use of biological agents in women of fertile age, the information was updated for the years 2006 and 2007. Experts disagree whether TNF-inhibitors should be stopped as soon as pregnancy is recognized or may be continued throughout pregnancy. Pregnancy experience with abatacept and rituximab is still too limited to prove their safety for the developing fetus. They must be withdrawn before a planned pregnancy. LEF has not been proven to be a human teratogen. Registries of transplant recipients have shown that cyclosporin (CsA) and tacrolimus do not increase the rate of congenital anomalies, whereas mycophenolate mofetil (MMF) clearly carries a risk for congenital anomalies. Prophylactic withdrawal of drugs before pregnancy is mandatory for abatacept, rituximab, LEF and MMF. Data remain insufficient for gonadal toxicity of immunosuppressive drugs in men and for excretion of these drugs in human breast milk